<DOC>
	<DOCNO>NCT00097370</DOCNO>
	<brief_summary>This open label study mepolizumab 750 mg intravenous subject participate study 100185 evaluate long term safety efficacy mepolizumab subject hypereosinophilic syndrome . The study also evaluate optimal dosing frequency clinical use , effect corticosteroid reduction , decrease sign symptom Hypereosinophilic Syndrome .</brief_summary>
	<brief_title>Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent . Subjects participate Study MHE100185 administer least 2 dos study medication . Not pregnant nursing Of nonchildbearing potential ( i.e. , woman hysterectomy , postmenopausal define 1 year without menses , ovary surgically remove , current document tubule ligation ) ; Of childbearing potential ( i.e. , woman functional ovary document impairment oviductal uterine function would cause sterility ) . This category include woman oligomenorrhoea [ even severe ] , woman perimenopausal begin menstruate . These woman must negative serum pregnancy test Screening Visit , agree one following:1 ) . Complete abstinence intercourse 2 week prior administration first dose investigational product 3 month last dose investigational product ; Or 2 ) . Consistent correct use one follow acceptable method birth control one month prior start investigation product three month last dose : Male partner sterile prior female subject 's entry study sole sexual partner female subject ; Implants levonorgestrel ; Injectable progestogen ; Any intrauterine device ( IUD ) document failure rate le 1 % per year ; Oral contraceptive ( either combine progestogen ) Exclusion criterion : Has develop lifethreatening serious illness clinical manifestation deem inappropriate inclusion study per principal investigator Has follow abnormal laboratory value Week36/EW Visit Study MHE100185 : • Serum creatinine ≥3 time institutional upper limit normal ( ULN ) ; • AST or/ALT ≥5 time institutional ULN ; • Platelet count &lt; 50,000/uL Has develop abnormal cardiac function , follow , within past 3 month : • Left ventricular ejection fraction ( LVEF ) &lt; 20 % ; • NYHA class IIIb IV ; • Angina acute myocardial infarction Has develop allergic reaction Study MHE100185 investigational product Use investigational drug concurrent medication Does complete Week36/EW Visit assessment require Study MHE100185 Has complete terminate Study MHE100185 1 month Recent history suspicion current drug abuse alcohol abuse within last 6 month Positive pregnancy test Week36/EW Visit Study MHE100185</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Mepolizumab</keyword>
	<keyword>Open-label</keyword>
	<keyword>Anti-IL-5</keyword>
	<keyword>Hypereosinophilic Syndrome</keyword>
	<keyword>Hypereosinophilia</keyword>
</DOC>